HAYWARD, Calif., May 17, 2017 /PRNewswire/ -- Impax Laboratories, Inc.
(NASDAQ: IPXL) today announced that Paul Bisaro, President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 24, 2017 at 10:30 a.m. Eastern Time.
Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 90 days.
About Impax Laboratories, Inc.Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.
For more information, please visit the Company's Web site at: www.impaxlabs.com.
Company Contact: Mark DonohueInvestor Relations and Corporate Communications (215) 558-4526 www.impaxlabs.com
Advertisement
Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 90 days.
Advertisement
About Impax Laboratories, Inc.Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.
For more information, please visit the Company's Web site at: www.impaxlabs.com.
Company Contact: Mark DonohueInvestor Relations and Corporate Communications (215) 558-4526 www.impaxlabs.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/impax-to-present-at-the-ubs-global-healthcare-conference-300459219.html
SOURCE Impax Laboratories, Inc.
